Talarozole R enantiomer

• CAT Number: I005237
• CAS Number: 870093-23-5
• Molecular Formula: C21H23N5S
• Molecular Weight: 377.51
• Purity: ≥95%
• Target: Cytochrome P450
• Solubility: DMSO: ≥ 51 mg/mL
• Storage: Store at -20°C
• IUPAC Name: N-[4-[(1R)-2-ethyl-1-(1,2,4-triazol-1-yl)butyl]phenyl]-1,3-benzothiazol-2-amine
• InChI: InChI=1S/C21H23N5S/c1-3-15(4-2)20(26-14-22-13-23-26)16-9-11-17(12-10-16)24-21-25-18-7-5-6-8-19(18)27-21/h5-15,20H,3-4H2,1-2H3,(H,24,25)/t20-/m1/s1
• InChIKey: SNFYYXUGUBUECJ-HXUWFJFHSA-N
• SMILES: CCC(CC)[C@H](C1=CC=C(C=C1)NC2=NC3=CC=CC=C3S2)N4C=NC=N4

Talarozole R enantiomer（Cat No.:I005237）is the active form of talarozole, a selective inhibitor of the enzyme retinoic acid-metabolizing cytochrome P450 (CYP26). CYP26 is responsible for the breakdown of retinoic acid, a vital metabolite of vitamin A involved in regulating gene expression, cellular differentiation, and development. By inhibiting this enzyme, talarozole R enantiomer increases retinoic acid levels, which may have therapeutic applications in skin disorders, such as acne or psoriasis, and potentially in cancer treatment. Research is ongoing to evaluate its efficacy, safety, and potential for clinical use in dermatology and oncology.